• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on therapeutic targets >Metastatic melanoma: the new era of targeted therapy.
【24h】

Metastatic melanoma: the new era of targeted therapy.

机译：转移性黑色素瘤：靶向治疗的新时代。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Metastatic melanoma is one of the most resistant tumors to standard chemotherapy, with a median overall survival of 6 - 8 months. Previously approved drugs offer only marginal survival advantages. Advances in the understanding of melanoma biology and host immunity have recently opened the field to new therapeutic approaches. Thus, after many years of disappointing results, a new era in the treatment of melanoma is beginning. AREAS COVERED: This review discusses new advances in the treatment of metastatic melanoma. Current data regarding the new agents under clinical development are reviewed, including emerging data from recently completed clinical trials, as well as preliminary data from ongoing studies testing novel therapeutic strategies. EXPERT OPINION: The new agents specifically targeted against melanoma are changing the standard of care for this disease. The monoclonal antibody ipilimumab is the first new agent approved for first- and second-line treatment of metastatic melanoma, based on improved overall survival compared -with standard therapy. Other drugs, such as BRAF inhibitors, have demonstrated high activity in the advanced disease and will be reaching clinical approval. Researchers are already planning ways to combine some of these new drugs in order to render possible a longer control of tumor.
机译：简介：转移性黑色素瘤是对标准化疗耐药性最高的肿瘤之一，中位总生存期为6-8个月。先前批准的药物仅提供边缘生存优势。对黑素瘤生物学和宿主免疫力的了解的最新进展最近为该领域开辟了新的治疗方法。因此，经过多年令人失望的结果，黑色素瘤治疗的新时代开始了。涵盖的领域：这篇综述讨论了转移性黑色素瘤治疗的新进展。审查了有关临床开发中的新药物的当前数据，包括最近完成的临床试验中的新兴数据，以及正在进行的测试新型治疗策略的研究中的初步数据。专家意见：专门针对黑色素瘤的新药物正在改变这种疾病的治疗标准。单克隆抗体ipilimumab是第一种被批准用于转移性黑色素瘤一线和二线治疗的新药，其基础是与标准疗法相比，其总生存期有所改善。其他药物，例如BRAF抑制剂，已在晚期疾病中显示出高活性，并将获得临床批准。研究人员已经在计划将这些新药中的一些结合起来的方法，以便更长久地控制肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号